An Open-Label Trial of Escitalopram in Children and Adolescents with Social Anxiety Disorder
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Social anxiety disorder (SAD) is a highly prevalent and disabling disorder in children and adolescents. This study was designed to evaluate the efficacy and safety of a highly potent and selective serotonin reuptake inhibitor, escitalopram, in the treatment of SAD in children and adolescents. Twenty outpatients with a primary diagnosis of SAD were treated in a 12-week open trial with escitalopram. The primary outcome variable was the change from baseline to end point in Clinical Global Impression-Improvement scale (CGI-I). Secondary efficacy measures included the CGI-Severity scale (CGI-S), the Social Phobia and Anxiety Inventory for Children (SPAI-C), the Screen for Child and Anxiety Related Emotional Disorders (SCARED)-Child and Parent version, and The Youth Quality of Life Instrument-Research Version (Y-QOL-R). On the CGI-I scale, 13 of 20 patients (65%) had a score < or =2, meaning response to treatment. All symptomatic and quality of life measures showed improvements from baseline to week 12, with large effect sizes ranging from 0.9 to 1.9 (all p < 0.001). Escitalopram was generally well-tolerated. These results suggest that escitalopram may be an effective and safe treatment for pediatric SAD. Future double-blind, placebo-controlled, randomized clinical trials are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BIRMAHER, B., KHETARPAL, S., BRENT, D., CULLY, M., BALACH, L., KAUFMAN, J., & NEER, S. M. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199704000-00018 · Cited by 2,846
BIRMAHER, B., BRENT, D. A., CHIAPPETTA, L., BRIDGE, J., MONGA, S., & BAUGHER, M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199910000-00011 · Cited by 2,252 · cited 2×
“The child’s anxiety symptoms were ascertained by children and parents using the Screen for Child and Anxiety Related Emotional Disorders (SCARED), Child (SCARED-C) and parent (SCARED-P) versions, respectively (Birma-her et al. 1997; Birmaher et al. 1999).”
Pine, D. S., Cohen, P., Gurley, D., Brook, J., & Ma, Y. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.56 · Cited by 1,753
Prevalence of mental disorders and psychosocial impairments in adolescents and young adults
WITTCHEN, H.-U., NELSON, C. B., & LACHNER, G. (1998) · Psychological Medicine · doi:10.1017/s0033291797005928 · Cited by 821 · cited 3×
“…disorder in children and adolescents, with life-time prevalence rates, according to Diagnostic and Statistical Manual of Mental Disorders , 4 th edition (DSM-IV) (American Psychiatric Association 1994) criteria, ranging from 0.7% (Bilyc-Fleitlich and Goodman 2004) to 3.5% (Wittchen et al. 1998).”
InfluentialFluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Stein, M. B., Fuetsch, M., Müller, N., Höfler, M., Lieb, R., & Wittchen, H.-U. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.251 · Cited by 573
The impairments caused by social phobia in the general population: implications for intervention
Kessler, R. C. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.2.x · Cited by 322 · cited 1×
“These individuals, as adults, frequently have significant impairment and disability in work and social functioning and reduced quality of life (Kessler 2003).”
Adolescent quality of life, Part II: initial validation of a new instrument
PATRICK, D. L., EDWARDS, T. C., & TOPOLSKI, T. D. (2002) · Journal of Adolescence · doi:10.1006/jado.2002.0471 · Cited by 260
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240 · cited 5×
“2001), citalopram combined with psychoeducation interventions (Chavira and Stein 2002), and one large, multicenter, randomized, 16 -week, double-blind, placebo-controlled trial with paroxetine (Wagner et al. 2004) suggest that treatments with selective serotonin reuptake inhibitors (SSRIs) are effective choices.”
Influential
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Wang, Z., Whiteside, S. P. H., Sim, L., Farah, W., Morrow, A. S., Alsawas, M., Barrionuevo, P., Tello, M., Asi, N., Beuschel, B., et al. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.3036 · Cited by 234
Offidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
Baldwin, D. S., Asakura, S., Koyama, T., Hayano, T., Hagino, A., Reines, E., & Larsen, K. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.013 · Cited by 36
Metadata
- Authors
- Isolan, L., Pheula, G., Salum, Jr., Oswald, S., Rohde, L. A., & Manfro, G. G.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2007-12
- Volume
- 17
- Issue
- 6
- Pages
- 751-760
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2032315567
- Cited by
- 60
- References
- 9
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Open-Label Trial of Escitalopram in Children and Adolescents with Social Anxiety Disorder. https://app.cochat.ai/papers/10.1089/cap.2007.0007
- The paper
- Isolan, L., Pheula, G., Salum, Jr., Oswald, S., Rohde, L. A., & Manfro, G. G. (2007). An Open-Label Trial of Escitalopram in Children and Adolescents with Social Anxiety Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2007.0007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.